Phase Ⅰ,ⅡStudy of Topically Applied Green Tea Extract for Prevention and Treatment of Radio Dermatitis and Radiation Mucositis

Trial Information
Who is this study for?Adult patients with radiation induced oral mucositis and dermatis
What treatments are being studied?Green tea extract EGCG
Status: Enrolling by invitation
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2

Radiodermatitis and radiation mucositis were the most frequent side-effect during the course of radiotherapy, especially when concurrent chemoradiotherapy applied. Since reactive oxygen species formed upon radiation therapy play a central role in initiating and driving the detrimental signaling events, antioxidant supplementation is thought to provide a photoprotective effect against radiation. Green tea extract has been shown to have antioxidant and anti-inflammatory effects on various types of cells. To evaluate the safety and efficiency of green tea extract in the treatment of radio dermatitis and radiation mucositis, the investigators conducted this phase Ⅰ,II study using topical EGCG in cancer patients receiving radiotherapy or concurrent chemoradiotherapy .

Am I eligible for this trial?
When is this trial taking place?
How many participants will be in this trial?
What treatment is being studied in this trial?
What other conditions are being studied in this trial?

This content was sourced from

A Phase 3, Open Label, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Efficacy of Ulinastatin in the Reduction of Acute Oral Mucositis Caused by Concurrent Chemoradiotherapy(CCRT) for Patients With Localregionally Advanced Nasopharyngeal Carcinoma (NPC).
Who is this study for:Adult patients with radiation-induced and chemo-induced oral mucositis
Start Date:January 30, 2018
Study Drug:Ulinastatin
Study Type:Drug, Radiation
Phase: Phase 3
The Open and Multi-center Phase III Clinical Study of Interleukin-11 in the Prevention and Treatment of Radioactive Oral Mucitis
Who is this study for:Adult patients with radiation and chemo-induced mucositis
Start Date:October 1, 2018
Study Drug:Recombinant Human Interleukin-11
Study Type:Drug
Phase: Phase 3